.

Pharmaceutical Business Intelligence

  • Predict branded drug patent expiration
  • Formulary management
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

TYGACIL Drug Profile

« Back to Dashboard

Which patents cover Tygacil, and what substitute generic drugs are available?

Tygacil is a drug marketed by Pf Prism Cv and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in twenty-seven countries.

The generic ingredient in TYGACIL is tigecycline. There are ten drug master file entries for this compound. Two suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the tigecycline profile page.

Summary for Tradename: TYGACIL

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list63
Clinical Trials: see list1
Patent Applications: see list1,138
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TYGACIL at DailyMed

Pharmacology for Tradename: TYGACIL

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
TYGACIL
tigecycline
POWDER;IV (INFUSION)021821-001Jun 15, 2005RXYesYes8,975,242► SubscribeY ► Subscribe
Pf Prism Cv
TYGACIL
tigecycline
POWDER;IV (INFUSION)021821-001Jun 15, 2005RXYesYes7,879,828► SubscribeY ► Subscribe
Pf Prism Cv
TYGACIL
tigecycline
POWDER;IV (INFUSION)021821-001Jun 15, 2005RXYesYes8,372,995► SubscribeY ► Subscribe
Pf Prism Cv
TYGACIL
tigecycline
POWDER;IV (INFUSION)021821-001Jun 15, 2005RXYesYes9,254,328► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TYGACIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv
TYGACIL
tigecycline
POWDER;IV (INFUSION)021821-001Jun 15, 20055,494,903► Subscribe
Pf Prism Cv
TYGACIL
tigecycline
POWDER;IV (INFUSION)021821-001Jun 15, 20055,529,990► Subscribe
Pf Prism Cv
TYGACIL
tigecycline
POWDER;IV (INFUSION)021821-001Jun 15, 2005RE40183► Subscribe
Pf Prism Cv
TYGACIL
tigecycline
POWDER;IV (INFUSION)021821-001Jun 15, 2005RE40086► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: TYGACIL

Drugname Dosage Strength RLD Submissiondate
tigecyclineFor Injection50 mg per vialTygacil6/15/2009

International Patent Family for Tradename: TYGACIL

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2006099258► Subscribe
Portugal1858488► Subscribe
Taiwan200700092► Subscribe
South Korea20080016890► Subscribe
Russian Federation2428190► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TYGACIL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB06/033United Kingdom► SubscribePRODUCT NAME: TIGECYCLINE
C0031France► SubscribePRODUCT NAME: TIGECYCLINE; REGISTRATION NO/DATE: EU/01/06/336/001 20060424
06/030Ireland► SubscribePRODUCT NAME: TIGECYCLINE OR A PHARMACOLOGICALLY ACCEPTABLE ORGANIC OR INORGANIC SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/06/336/001 20060424
00244Netherlands► SubscribePRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424
0244Netherlands► SubscribePRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc